Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

Naoki Aikawa; Junichi Sasaki; Shigetomi Iwai; Masahiko Kunimatsu; Hisashi Furuhata; Tetsuya Watanabe; Hideki Matsuyama; Yuji Sugiyama; Takeaki Shimizu; Nagao Shinagawa; Keiji Mashita; Tadao Manabe; Shu Ishikawa; Akira Mizuno; Akihiko Iwai; Kazuaki Matsumoto; Keiichi Hori; Hiroaki Kinoshita; Shoji Kubo; Hiromu Tanaka; Takami Ueda; Mikio Fujimoto; Shuichi Nakatani; Ryutaro Iwasa; Osamu Yamazaki; Takashi Yokoyama; Takashi Kodama; Nobukazu Miyoshi; Yasushi Maruyama; Akihiro Kishi; Gen Takesawa; Seiji Matsuda; Hiroji Okada; Yoshinori Nakata; Jiro Okumura; Tadashi Obata; Shigeatsu Endo; Kazuyoshi Saito; Yoshiki Takahashi; Yoshimi Osakabe; Chiiho Fujii; Mitsuhiro Fukuda

Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

Naoki Aikawa, Junichi Sasaki, Shigetomi Iwai, Masahiko Kunimatsu, Hisashi Furuhata, Tetsuya Watanabe, Hideki Matsuyama, Yuji Sugiyama, Takeaki Shimizu, Nagao Shinagawa, Keiji Mashita, Tadao Manabe, Shu Ishikawa, Akira Mizuno, Akihiko Iwai, Kazuaki Matsumoto, Keiichi Hori, Hiroaki Kinoshita, Shoji Kubo, Hiromu TanakaTakami Ueda, Mikio Fujimoto, Shuichi Nakatani, Ryutaro Iwasa, Osamu Yamazaki, Takashi Yokoyama, Takashi Kodama, Nobukazu Miyoshi, Yasushi Maruyama, Akihiro Kishi, Gen Takesawa, Seiji Matsuda, Hiroji Okada, Yoshinori Nakata, Jiro Okumura, Tadashi Obata, Shigeatsu Endo, Kazuyoshi Saito, Yoshiki Takahashi, Yoshimi Osakabe, Chiiho Fujii, Mitsuhiro Fukuda

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.

Original language	English
Pages (from-to)	948-950
Number of pages	3
Journal	Japanese Journal of Chemotherapy
Volume	45
Issue number	11
Publication status	Published - 1997

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Cite this

Aikawa, N., Sasaki, J., Iwai, S., Kunimatsu, M., Furuhata, H., Watanabe, T., Matsuyama, H., Sugiyama, Y., Shimizu, T., Shinagawa, N., Mashita, K., Manabe, T., Ishikawa, S., Mizuno, A., Iwai, A., Matsumoto, K., Hori, K., Kinoshita, H., Kubo, S., ... Fukuda, M. (1997). Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields. Japanese Journal of Chemotherapy, 45(11), 948-950.

Aikawa, N, Sasaki, J, Iwai, S, Kunimatsu, M, Furuhata, H, Watanabe, T, Matsuyama, H, Sugiyama, Y, Shimizu, T, Shinagawa, N, Mashita, K, Manabe, T, Ishikawa, S, Mizuno, A, Iwai, A, Matsumoto, K, Hori, K, Kinoshita, H, Kubo, S, Tanaka, H, Ueda, T, Fujimoto, M, Nakatani, S, Iwasa, R, Yamazaki, O, Yokoyama, T, Kodama, T, Miyoshi, N, Maruyama, Y, Kishi, A, Takesawa, G, Matsuda, S, Okada, H, Nakata, Y, Okumura, J, Obata, T, Endo, S, Saito, K, Takahashi, Y, Osakabe, Y, Fujii, C & Fukuda, M 1997, 'Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields', Japanese Journal of Chemotherapy, vol. 45, no. 11, pp. 948-950.

@article{e78630e6f8b0401080ad767e2f7e44b4,

title = "Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields",

abstract = "A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.",

author = "Naoki Aikawa and Junichi Sasaki and Shigetomi Iwai and Masahiko Kunimatsu and Hisashi Furuhata and Tetsuya Watanabe and Hideki Matsuyama and Yuji Sugiyama and Takeaki Shimizu and Nagao Shinagawa and Keiji Mashita and Tadao Manabe and Shu Ishikawa and Akira Mizuno and Akihiko Iwai and Kazuaki Matsumoto and Keiichi Hori and Hiroaki Kinoshita and Shoji Kubo and Hiromu Tanaka and Takami Ueda and Mikio Fujimoto and Shuichi Nakatani and Ryutaro Iwasa and Osamu Yamazaki and Takashi Yokoyama and Takashi Kodama and Nobukazu Miyoshi and Yasushi Maruyama and Akihiro Kishi and Gen Takesawa and Seiji Matsuda and Hiroji Okada and Yoshinori Nakata and Jiro Okumura and Tadashi Obata and Shigeatsu Endo and Kazuyoshi Saito and Yoshiki Takahashi and Yoshimi Osakabe and Chiiho Fujii and Mitsuhiro Fukuda",

year = "1997",

language = "English",

volume = "45",

pages = "948--950",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

number = "11",

}

TY - JOUR

T1 - Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

AU - Aikawa, Naoki

AU - Sasaki, Junichi

AU - Iwai, Shigetomi

AU - Kunimatsu, Masahiko

AU - Furuhata, Hisashi

AU - Watanabe, Tetsuya

AU - Matsuyama, Hideki

AU - Sugiyama, Yuji

AU - Shimizu, Takeaki

AU - Shinagawa, Nagao

AU - Mashita, Keiji

AU - Manabe, Tadao

AU - Ishikawa, Shu

AU - Mizuno, Akira

AU - Iwai, Akihiko

AU - Matsumoto, Kazuaki

AU - Hori, Keiichi

AU - Kinoshita, Hiroaki

AU - Kubo, Shoji

AU - Tanaka, Hiromu

AU - Ueda, Takami

AU - Fujimoto, Mikio

AU - Nakatani, Shuichi

AU - Iwasa, Ryutaro

AU - Yamazaki, Osamu

AU - Yokoyama, Takashi

AU - Kodama, Takashi

AU - Miyoshi, Nobukazu

AU - Maruyama, Yasushi

AU - Kishi, Akihiro

AU - Takesawa, Gen

AU - Matsuda, Seiji

AU - Okada, Hiroji

AU - Nakata, Yoshinori

AU - Okumura, Jiro

AU - Obata, Tadashi

AU - Endo, Shigeatsu

AU - Saito, Kazuyoshi

AU - Takahashi, Yoshiki

AU - Osakabe, Yoshimi

AU - Fujii, Chiiho

AU - Fukuda, Mitsuhiro

PY - 1997

Y1 - 1997

N2 - A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.

AB - A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.

UR - http://www.scopus.com/inward/record.url?scp=0031393637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031393637&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031393637

SN - 1340-7007

VL - 45

SP - 948

EP - 950

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

IS - 11

ER -

Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this